Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)-Reference-Cited by-同舟云学术

Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)

Published:2010-03-30 Issue:7 Volume:85 Page:477-481
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Middeldorf Iris,Galm Oliver,Osieka Rainhardt,Jost Edgar,Herman James G.,Wilop Stefan

Publisher

Wiley

Subject

Hematology

Reference43 articles.

1. Acute myeloid leukemia: Epidemiology and etiology;Deschler;Cancer,2006

2. Current and emerging strategies for the management of acute myeloid leukemia in the elderly;Laubach;Oncologist,2008

3. Acute myeloid leukemia;Lowenberg;N Engl J Med,1999

4. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties;Wheatley;Br J Haematol,1999

5. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia;Ferrara;Haematologica,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to targeted therapies in acute myeloid leukemia;Clinical & Experimental Metastasis;2022-11-01

2. Thymoquinone Inhibits Growth of Acute Myeloid Leukemia Cells through Reversal SHP-1 and SOCS-3 Hypermethylation: In Vitro and In Silico Evaluation;Pharmaceuticals;2021-12-09

3. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment;International Journal of Molecular Sciences;2020-08-06

4. PLA2G4A Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/NPM1 Wildtype Acute Myeloid Leukemia;DNA and Cell Biology;2020-04-01

5. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia;Future Oncology;2018-12